Seven Grand Managers LLC Invests $2.33 Million in Kymera Therapeutics, Inc. $KYMR

Key Points

• Seven Grand Managers LLC opened a new position in Kymera Therapeutics in the fourth quarter, buying 30,000 shares valued at about $2.33 million.
• Recent insider selling has been significant: Director Bruce Booth and CEO Nello Mainolfi both sold shares, and insiders sold 370,918 shares worth $31.1 million over the last three months.
• Kymera reported a better-than-expected quarterly loss and much stronger revenue growth, while analysts remain broadly positive with a Moderate Buy consensus and a target price around $118.10.

Seven Grand Managers LLC purchased a new position in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 30,000 shares of the company's stock, valued at approximately $2,334,000.

Several other hedge funds have also recently modified their holdings of KYMR. Larson Financial Group LLC lifted its position in shares of Kymera Therapeutics by 81.5% in the 3rd quarter. Larson Financial Group LLC now owns 777 shares of the company's stock worth $44,000 after purchasing an additional 349 shares during the period. Osaic Holdings Inc. lifted its position in shares of Kymera Therapeutics by 18,050.0% in the 2nd quarter. Osaic Holdings Inc. now owns 1,089 shares of the company's stock worth $48,000 after purchasing an additional 1,083 shares during the period. Bessemer Group Inc. lifted its position in shares of Kymera Therapeutics by 652.0% in the 3rd quarter. Bessemer Group Inc. now owns 940 shares of the company's stock worth $53,000 after purchasing an additional 815 shares during the period. Raymond James Financial Inc. purchased a new stake in shares of Kymera Therapeutics in the 2nd quarter worth approximately $73,000. Finally, US Bancorp DE lifted its position in shares of Kymera Therapeutics by 9.8% in the 3rd quarter. US Bancorp DE now owns 1,865 shares of the company's stock worth $106,000 after purchasing an additional 166 shares during the period.

Insiders Place Their Bets

In related news, Director Bruce Booth sold 5,900 shares of the firm's stock in a transaction on Wednesday, April 22nd. The shares were sold at an average price of $89.96, for a total transaction of $530,764.00. Following the completion of the transaction, the director owned 5,641 shares of the company's stock, valued at $507,464.36. This trade represents a 51.12% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Nello Mainolfi sold 30,000 shares of the company's stock in a transaction on Wednesday, April 29th. The shares were sold at an average price of $81.18, for a total transaction of $2,435,400.00. Following the completion of the sale, the chief executive officer directly owned 666,195 shares in the company, valued at approximately $54,081,710.10. The trade was a 4.31% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 370,918 shares of company stock worth $31,120,324. Company insiders own 15.98% of the company's stock.

Kymera Therapeutics Trading Up 1.2%

NASDAQ:KYMR opened at $81.70 on Thursday. The company has a market cap of $6.72 billion, a PE ratio of -22.89 and a beta of 2.06. Kymera Therapeutics, Inc. has a twelve month low of $28.33 and a twelve month high of $103.00. The company's 50 day moving average is $83.28 and its two-hundred day moving average is $79.14.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last released its earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share for the quarter, topping the consensus estimate of ($0.89) by $0.18. The company had revenue of $34.37 million for the quarter, compared to the consensus estimate of $8.27 million. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. Kymera Therapeutics's revenue was up 55.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.82) EPS. As a group, analysts expect that Kymera Therapeutics, Inc. will post -3.34 EPS for the current fiscal year.

Analysts Set New Price Targets

KYMR has been the subject of several research reports. Piper Sandler boosted their price objective on shares of Kymera Therapeutics from $125.00 to $140.00 and gave the stock an "overweight" rating in a research note on Thursday, February 26th. Royal Bank Of Canada reiterated an "outperform" rating and set a $108.00 price objective on shares of Kymera Therapeutics in a research note on Thursday, February 26th. Citigroup boosted their price objective on shares of Kymera Therapeutics from $110.00 to $120.00 and gave the stock a "buy" rating in a research note on Monday, March 2nd. Weiss Ratings reiterated a "sell (d-)" rating on shares of Kymera Therapeutics in a research note on Tuesday, April 21st. Finally, Morgan Stanley reiterated an "overweight" rating and set a $119.00 price objective on shares of Kymera Therapeutics in a research note on Thursday, April 30th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $118.10.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body's natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company's proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company's pipeline emphasizes immunology and oncology.

Want to see what other hedge funds are holding KYMR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.